Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPG7236 Combined With Toripalimab in Advanced Solid Tumors
NCT07508761Phase 2Recruiting
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IPG7236 in solid tumor (advanced stage), sponsored by Nanjing Immunophage Biotech Co., Ltd.. Started Jun 2026; status: recruiting.
02
Drugs
IPG7236
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07508761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07508761.